Page last updated: 2024-10-29

ketamine and Ulcer

ketamine has been researched along with Ulcer in 7 studies

Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.

Ulcer: A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue.

Research Excerpts

ExcerptRelevanceReference
"Long-term abuse of ketamine causes ketamine-induced cystitis."7.96Extracellular vesicles enhance oxidative stress through P38/NF-kB pathway in ketamine-induced ulcerative cystitis. ( Chen, SH; He, PJ; Jiang, ZW; Lu, Y; Mi, H; Xi, XJ; Zeng, JJ, 2020)
"Immunoglobulin E, ketamine cystitis, interstitial cystitis."7.83The Role of Immunoglobulin E in the Pathogenesis of Ketamine Related Cystitis and Ulcerative Interstitial Cystitis: An Immunohistochemical Study. ( Hsu, YH; Jhang, JF; Jiang, YH; Kuo, HC, 2016)
"This case series has described a new clinical entity of severe ulcerative cystitis as a result of chronic ketamine use."7.74Ketamine-associated ulcerative cystitis: a new clinical entity. ( Dickson, B; Shahani, R; Stewart, RJ; Streutker, C, 2007)
"Ketamine-treated rats were found to display bladder hyperactivity."5.42Ketamine-induced ulcerative cystitis and bladder apoptosis involve oxidative stress mediated by mitochondria and the endoplasmic reticulum. ( Chuang, SM; Ho, WT; Jang, MY; Juan, YS; Lee, YL; Lin, RJ; Liu, KM; Long, CY; Lu, JH; Lu, MC; Wang, CC; Wu, WJ, 2015)
"Long-term abuse of ketamine causes ketamine-induced cystitis."3.96Extracellular vesicles enhance oxidative stress through P38/NF-kB pathway in ketamine-induced ulcerative cystitis. ( Chen, SH; He, PJ; Jiang, ZW; Lu, Y; Mi, H; Xi, XJ; Zeng, JJ, 2020)
"Immunoglobulin E, ketamine cystitis, interstitial cystitis."3.83The Role of Immunoglobulin E in the Pathogenesis of Ketamine Related Cystitis and Ulcerative Interstitial Cystitis: An Immunohistochemical Study. ( Hsu, YH; Jhang, JF; Jiang, YH; Kuo, HC, 2016)
"This case series has described a new clinical entity of severe ulcerative cystitis as a result of chronic ketamine use."3.74Ketamine-associated ulcerative cystitis: a new clinical entity. ( Dickson, B; Shahani, R; Stewart, RJ; Streutker, C, 2007)
"Ketamine-treated rats were found to display bladder hyperactivity."1.42Ketamine-induced ulcerative cystitis and bladder apoptosis involve oxidative stress mediated by mitochondria and the endoplasmic reticulum. ( Chuang, SM; Ho, WT; Jang, MY; Juan, YS; Lee, YL; Lin, RJ; Liu, KM; Long, CY; Lu, JH; Lu, MC; Wang, CC; Wu, WJ, 2015)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19901 (14.29)18.7374
1990's0 (0.00)18.2507
2000's3 (42.86)29.6817
2010's2 (28.57)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Xi, XJ1
Zeng, JJ1
Lu, Y1
Chen, SH1
Jiang, ZW1
He, PJ1
Mi, H1
Liu, KM1
Chuang, SM1
Long, CY1
Lee, YL1
Wang, CC1
Lu, MC1
Lin, RJ1
Lu, JH1
Jang, MY1
Wu, WJ1
Ho, WT1
Juan, YS1
Jhang, JF1
Hsu, YH1
Jiang, YH1
Kuo, HC1
Shahani, R2
Streutker, C1
Dickson, B1
Stewart, RJ2
Okon, T1
Gaertner, DJ1
Boschert, KR1
Schoeb, TR1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Intravesical Injection of Dextrose to Improve Lower Urinary Tract Symptoms Caused by Chronic Cystitis[NCT04821882]29 participants (Actual)Interventional2019-05-01Completed
Oral Ketamine for Control of Chronic Pain in Children[NCT01369680]Phase 112 participants (Actual)Interventional2011-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Neurocognitive Effect

"Baseline neurocognitive testing will be done before study drug is given. Subjects will be reassessed for any changes in neurocognitive scores at end of dosing (week 2) and at three weeks off study drug (week 14). Significant changes were measured at week 14 compared to baseline. Week 2 was measured to inform future studies.~The neurocognitive scores are standardized scores with a mean of 100; low scores correlate with low neurocognitive function, while high scores correlate with high function. A significant change is defined as greater than or equal to 10% decrease in scores." (NCT01369680)
Timeframe: At 14 weeks

Interventionparticipants (Number)
Ketamine 0.25 mg/kg/Dose0
Ketamine 0.5 mg/kg/Dose0
Ketamine 1 mg/kg/Dose0
Ketamine 1.5 mg/kg/Dose0

Norketamine Cmax (Measured in ng/mL).

Pharmacokinetic testing will be done during chronic ketamine administration on subjects consenting to additional testing one week into study drug administration. This is to further describe the activity of ketamine in the blood of children when administered chronically and to enable comparison of any clinical effect or toxicity with steady state levels of ketamine in children. (NCT01369680)
Timeframe: At week 1

Interventionng/mL (Mean)
Ketamine 0.25 mg/kg/Dose37.5
Ketamine 0.5 mg/kg/Dose135
Ketamine 1 mg/kg/Dose250

Number of Participants Tolerating Dose

According to CTCae any dose causing grade 2 or worse toxicity will be an untolerated dose. Tolerability is defined as ability to take the medication for 2 weeks without having a grade 2 or worse toxicity. (NCT01369680)
Timeframe: Up to 2 weeks

Interventionparticipants (Number)
Ketamine 0.25 mg/kg/Dose3
Ketamine 0.5 mg/kg/Dose3
Ketamine 1 mg/kg/Dose3
Ketamine 1.5 mg/kg/Dose1

Pain Control

"Subjects will be assessed for clinically significant change in pain scores during and after study drug administration. Significant change in pain scores were determined at week 2, though week 14 scores were collected as well.~Participants with a 2 point (or greater) decrease in pain scores compared to baseline were considered to have responded. The NRS scale was used, the scale ranges from 0-10, with 10 being the most pain." (NCT01369680)
Timeframe: Week 2

Interventionparticipants (Number)
Ketamine 0.25 mg/kg/Dose3
Ketamine 0.5 mg/kg/Dose0
Ketamine 1 mg/kg/Dose2
Ketamine 1.5 mg/kg/Dose0

Reviews

1 review available for ketamine and Ulcer

ArticleYear
Ketamine: an introduction for the pain and palliative medicine physician.
    Pain physician, 2007, Volume: 10, Issue:3

    Topics: Adult; Amines; Analgesics; Analgesics, Opioid; Central Nervous System; Cryoglobulinemia; Cyclohexane

2007

Other Studies

6 other studies available for ketamine and Ulcer

ArticleYear
Extracellular vesicles enhance oxidative stress through P38/NF-kB pathway in ketamine-induced ulcerative cystitis.
    Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:13

    Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Cystitis; Cytochalasin D; Extracellular Vesicles; Humans

2020
Ketamine-induced ulcerative cystitis and bladder apoptosis involve oxidative stress mediated by mitochondria and the endoplasmic reticulum.
    American journal of physiology. Renal physiology, 2015, Aug-15, Volume: 309, Issue:4

    Topics: Animals; Antioxidants; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers; Cystitis; Disease Model

2015
The Role of Immunoglobulin E in the Pathogenesis of Ketamine Related Cystitis and Ulcerative Interstitial Cystitis: An Immunohistochemical Study.
    Pain physician, 2016, Volume: 19, Issue:4

    Topics: Adult; Aged; Biomarkers; Cystitis, Interstitial; Female; Humans; Immunoglobulin E; Ketamine; Male; M

2016
Ketamine-associated ulcerative cystitis: a new clinical entity.
    Urology, 2007, Volume: 69, Issue:5

    Topics: Adult; Biopsy, Needle; Cystitis; Cystoscopy; Female; Follow-Up Studies; Humans; Ketamine; Male; Pent

2007
Reply to letter-to-the-editor, Re: Shahani R, Streutker C, Dickson B, et al: Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 69: 810-812, 2007.
    Urology, 2008, Volume: 71, Issue:5

    Topics: Analgesics; Cystitis; Humans; Ketamine; Ulcer

2008
Muscle necrosis in Syrian hamsters resulting from intramuscular injections of ketamine and xylazine.
    Laboratory animal science, 1987, Volume: 37, Issue:1

    Topics: Animals; Cricetinae; Drug Combinations; Female; Injections, Intramuscular; Ketamine; Mesocricetus; M

1987
chemdatabank.com